Pazopanib

Pazopanib is a multi-targeted tyrosine kinase inhibitor approved for the treatment of advanced renal cell carcinoma and soft tissue sarcoma, marketed as Votrient®. As a potent inhibitor of VEGFR1, VEGFR2, and VEGFR3 (IC₅₀ = 10, 30, and 47 nM, respectively), Pazopanib effectively blocks angiogenesis by inhibiting VEGF-mediated signaling. Pazopanib also inhibits PDGFRα, PDGFRβ, and c-Kit (IC₅₀ = 71, 84, and 74 nM, respectively), as well as additional receptor tyrosine kinases, contributing to its broad anti-tumor activity. For pharmaceutical quality control and analytical development, Pazopanib serves as an essential reference standard for impurity profiling, method validation, and stability studies in generic manufacturing. Pazopanib is also a key reference material for ANDA filings, supporting the development of generic versions of this important oncology drug.

Product Parameters

---

Parameter	Specification
Product Name	Pazopanib
CAS Number	444731-52-6
Molecular Formula	C₂₁H₂₃N₇O₂S
Molecular Weight	437.52 g/mol
Physical Form	White powder
Density	1.40 g/cm³ (predicted)
Boiling Point	728.8 ± 70.0 °C at 760 mmHg
Melting Point	285-289 °C
Storage Condition	Refrigerator

Indication

---

Pazopanib is an oral, multi-target tyrosine kinase inhibitor that blocks multiple receptors including VEGFR1-3, PDGFR-α, PDGFR-β, and c-KIT, with a mechanism of action highly similar to that of sorafenib and sunitinib. In October 2009, the FDA officially approved pazopanib as a first-line treatment for advanced renal cell carcinoma. Following Novartis's acquisition of GlaxoSmithKline's oncology drug division, pazopanib is now marketed by Novartis. Indications for pazopanib:

1.FDA approved for use in patients with advanced renal cancer.

 

2.The FDA has approved its use in patients with advanced soft tissue sarcoma (STS) who have previously received chemotherapy.

However, the efficacy of pazotinib in liposarcomas or gastric stromal tumors has not been established. Trial data on soft tissue sarcoma treatment: In a Phase III clinical trial (EORTC 62072),368 patients with metastatic non-liposarcomal STS who had previously failed anthracycline-based chemotherapy received either pazotinib or placebo, demonstrating a significant improvement in progression-free survival (PFS) by 4.6 months versus 1.6 months.

 

Bioactivity

---

Pazopanib (GW786034) is a novel multi-target inhibitor targeting VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit, and c-Fms/CSF1R, with IC50 values of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM, and 146 nM, respectively, in cell-free assays. Pazopanib can induce the activation of cathepsin B and autophagy.

 

Contact Us

---

Need Pazopanib for your oncology API manufacturing campaign, impurity profiling program, or kinase research? Cosperpharm is here to help. Reach out to our team for pricing, documentation, or technical support—we'll get back to you promptly.